

# **Efficacy of Direct Ethanol Sclerotherapy in Management of Low Flow Congenital Vascular Malformations**

Thesis submitted for partial fulfillment of  
MD degree in Vascular Surgery

By  
**Mohammed Hassan Aly Abou Mansour**

M.B.B.Ch, M.sc, of General Surgery

Supervised by

**Prof. Dr. Mostafa Soliman Mahmoud**

Professor of General and Vascular Surgery  
Faculty of medicine - Ain Shams University

**Prof. Dr. Tarek Mohammed Radwan**

Professor of Vascular Surgery  
Military medical academy

**Dr. Nader Mohammed Mohammed Hamada**

Lecturer of Vascular Surgery  
Faculty of Medicine - Ain Shams University

Faculty of Medicine  
Ain Shams University  
2019

# *Acknowledgment*

*Before all and above all thanks to **ALLAH**, for without his blessing, this work would have never been accomplished.*

*I would like to express my deepest and most sincere thanks and gratitude to **Prof. Dr. Mostafa Soliman Mahmoud**, professor of Vascular Surgery Faculty of Medicine –Ain Shams University for his valuable assistance and support.*

*I am most obliged to **Prof. Dr. Tarek Mohammed Radwan**, professor of vascular surgery, military medical academy, for generous and most helpful contribution, advices, and for his marvelous support.*

*To **Dr. Nader Mohammed Hamada**, lecturer of vascular surgery, Faculty of Medicine –Ain Shams University, I would like to thank you for your generous and nonstop contribution.*

*Thanks to **prof. Dr. Wayne Yakes**, who I learned so much from him about vascular anomalies.*

*To **my all family & to my friend Dr. Abd Elwahab Hashem**, for their support and effort and their endless nonstop help through the whole way, I ask Allah, to give them what they wish.*

*To the **patients with vascular anomalies**, their families, and colleagues who participate in the care of and research in this field.*

*Mohammed Abou Mansour*

## **List of Contents**

|  |     |
|--|-----|
| Introduction .....                     | 1   |
| Aim of study.....                      | 4   |
| Review .....                           | 5   |
| I.    CVMs embryology & genetic aspect | 5   |
| II.   Epidemiology & classifications   | 18  |
| III.  Diagnostic criteria              | 37  |
| IV.   Treatment modalities             | 59  |
| V.    Treatment complications          | 99  |
| Patients and methods .....             | 120 |
| Results .....                          | 142 |
| Discussion .....                       | 171 |
| Summary .....                          | 183 |
| Conclusion & recommendations .....     | 187 |
| Reference .....                        | 188 |
| Arabic Summary                         | ١   |

## **List of Abbreviations**

|                |  |
|----------------|--|
| <b>AM</b>      | Arterial malformation  |
| <b>AVM</b>     | Arterio-venous malformation  |
| <b>AVF</b>     | Arterio-venous fistula   |
| <b>BCMSP</b>   | Bogota Congenital Malformations Surveillance program                             |
| <b>CBC</b>     | Complete blood count   |
| <b>CLVM</b>    | Cappillary lymphatico-venous malformation  |
| <b>CM</b>      | Cappillary malformation  |
| <b>CT</b>      | Computed tomography  |
| <b>CVM</b>     | Congenital vascular malformation   |
| <b>dceMRI</b>  | Dynamic contrast enhanced MRI  |
| <b>DIC</b>     | Disseminated intravascular coagulopathy  |
| <b>DMSO</b>    | Dimethyl sulfoxide   |
| <b>DUS</b>     | Duplex ultrasound  |
| <b>EUROCAT</b> | European Surveillance of Congenital Anomalies                                    |
| <b>EVOH</b>    | Ethylene vinyl alcohol   |
| <b>FR</b>      | French   |
| <b>GLOVES</b>  | Congenital lipomatous overgrowth with vascular, epidermal and skeletal anomalies |
| <b>HLM</b>     | Hemolymphatic malformation   |
| <b>IBCA</b>    | Isobutyl 2-cyanoacrylate   |
| <b>ICU</b>     | Intensive care unit  |
| <b>IMC</b>     | International Medical Center   |
| <b>INR</b>     | International normalized ratio   |
| <b>IPEH</b>    | Intra vascular papillary endothelial hyperplasia                                 |
| <b>ISSVA</b>   | International Society for the Study of Vascular Anomalies                        |
| <b>KTS</b>     | Klippel-Trenaunay syndrome   |
| <b>LIC</b>     | localized intravascular coagulation  |
| <b>LM</b>      | Lymphatic malformation   |
| <b>MRI</b>     | Magnetic resonance imaging   |
| <b>mTOR</b>    | mammalian target of rapamycin  |
| <b>NBCA</b>    | N-butyl cyanoacrylate  |
| <b>NSAID</b>   | Non-steroidal anti-inflammatory agents   |
| <b>PAP</b>     | Pulmonary artery pressure  |
| <b>PKB</b>     | Protein kinase B   |
| <b>POL</b>     | Polidocanol  |
| <b>PT</b>      | Prothrombin time   |

|              |  |
|--------------|--|
| <b>PTT</b>   | Partial thromboplastin time                |
| <b>PVA</b>   | Polyvinyl alcohol particles                |
| <b>RBCs</b>  | Red blood cells                            |
| <b>SD</b>    | Standard deviation                         |
| <b>SPECT</b> | Single-photon emission computed tomography |
| <b>STIR</b>  | Short-tau inversion recovery               |
| <b>STS</b>   | Sodium tetradecyl sulfate                  |
| <b>TALPS</b> | Trans arterial lung perfusion scintigraphy |
| <b>TIE2</b>  | tyrosine-protein kinase receptor           |
| <b>VAR</b>   | Veno-arteriolar reflex                     |
| <b>VM</b>    | Venous malformation                        |
| <b>WBBPS</b> | Whole-body blood pool scan                 |

## List of Figures

| <b>Figure No.</b> | <b>Title</b>   | <b>Page</b> |
|-------------------|--|-------------|
| <b>Fig (1)</b>    | Vascular system development  | <b>5</b>    |
| <b>Fig (2)</b>    | Embryonic lymphatics at the seventh week of gestation  | <b>9</b>    |
| <b>Fig (3)</b>    | Extensive VM at Lt Shoulder, chest & upper limb  | <b>42</b>   |
| <b>Fig (4)</b>    | Venous malformation Lt Check & lips  | <b>44</b>   |
| <b>Fig (5)</b>    | Diffuse VM of the lower extremity  | <b>45</b>   |
| <b>Fig (6)</b>    | Puig's (Angiographic) classification of VMs  | <b>52</b>   |
| <b>Fig (7)</b>    | LM ultrasound  | <b>56</b>   |
| <b>Fig (8)</b>    | LM Rt shoulder & chest + MRI showing hyperintense T2   | <b>56</b>   |
| <b>Fig (9)</b>    | VM sclerotherapy steps   | <b>71</b>   |
| <b>Fig (10)</b>   | VM forearm pre & post sclerotherapy  | <b>76</b>   |
| <b>Fig (11)</b>   | VM lower lip pre & post-surgical removal   | <b>87</b>   |
| <b>Fig (12)</b>   | Superficial venous malformation in the left lower limb with skin nevus and dysplastic veins, located in an atypical area | <b>91</b>   |
| <b>Fig (13)</b>   | Exposed popliteal venous aneurysm  | <b>92</b>   |
| <b>Fig (14)</b>   | Fingertip ischemia post ethanol sclerotherapy  | <b>102</b>  |
| <b>Fig (15)</b>   | MRI head in three sections shows Rt. check VM  | <b>130</b>  |
| <b>Fig (16)</b>   | Blood obtained through the butterfly needle in VM  | <b>131</b>  |
| <b>Fig (17)</b>   | Lymphatic aspiration within a syringe in LM  | <b>132</b>  |
| <b>Fig (18)</b>   | Contrast injection (Direct puncture venography)  | <b>132</b>  |
| <b>Fig (19)</b>   | Ethanol sclerotherapy  | <b>133</b>  |
| <b>Fig (20)</b>   | Post ethanol sclerotherapy puncture site bleeding management   | <b>134</b>  |
| <b>Fig (21)</b>   | patient's age  | <b>142</b>  |
| <b>Fig (22)</b>   | Malformation type  | <b>144</b>  |
| <b>Fig (23)</b>   | Malformation distributions   | <b>145</b>  |
| <b>Fig (24)</b>   | Mean presenting symptoms   | <b>146</b>  |
| <b>Fig (25)</b>   | Ulcer at Rt. Foot dorsum post ethanol sclerotherapy  | <b>150</b>  |
| <b>Fig (26)</b>   | a) VM Lt. Side forehead just pre procedure   | <b>152</b>  |
|                   | b) Pre procedure MRI coronal, transverse & sagittal views  | <b>153</b>  |
|                   | c) Venography, sclerotherapy & Photo just post   | <b>153</b>  |

| <b>Figure No.</b> | <b>Title</b>   | <b>Page</b> |
|-------------------|--|-------------|
|                   | sclerotherapy  |             |
|                   | d) MRI 2 months post procedure   | <b>154</b>  |
|                   | e) Clinical improvement 2 months post procedure  | <b>154</b>  |
| <b>Fig (27)</b>   | a) LM Lt. Side face just pre procedure   | <b>155</b>  |
|                   | b) Pre procedure MRI coronal view  | <b>156</b>  |
|                   | c) Lymphatic aspiration, venography & sclerotherapy  | <b>156</b>  |
|                   | d) MRI 2 months post procedure   | <b>156</b>  |
|                   | e) Clinical improvement 2 months post procedure  | <b>157</b>  |
| <b>Fig (28)</b>   | a) VM Rt. hand   | <b>158</b>  |
|                   | b) Pre procedure MRI coronal & transverse views  | <b>159</b>  |
|                   | c) Venography & sclerotherapy  | <b>159</b>  |
|                   | d) MRI 2 months post procedure   | <b>159</b>  |
|                   | e) Clinical improvement 2 months post procedure follow up  | <b>160</b>  |
| <b>Fig (29)</b>   | Comparison between pre & post-procedure MRIs showing marked radiological improvement of some cases | <b>161</b>  |
|                   | a) Right Side face & tongue VLM treated by ethanol sclerotherapy                                   | <b>161</b>  |
|                   | b) Lt. side face & submandibular VM treated by ethanol sclerotherapy                               | <b>162</b>  |
|                   | c) Left side face & upper neck VM treated by ethanol sclerotherapy                                 | <b>163</b>  |
|                   | d) Left lower limb VM treated by ethanol sclerotherapy   | <b>164</b>  |
|                   | e) D) Distal fore arm VM treated by ethanol sclerotherapy  | <b>165</b>  |
|                   | f) Left Side face & peri orbital VM treated by ethanol sclerotherapy                               | <b>166</b>  |
|                   | g) Right lower limb VM treated by ethanol sclerotherapy  | <b>167</b>  |
|                   | h) VM anterior lateral aspects of Rt. Thigh treated by ethanol sclerotherapy                       | <b>168</b>  |
|                   | i) hand VM treated by ethanol sclerotherapy  | <b>169</b>  |
|                   | j) VM at upper forearm treated by ethanol sclerotherapy  | <b>170</b>  |

## List of Tables

| <b>Table No.</b>  | <b>Title</b>  | <b>Page</b> |
|-------------------|---|-------------|
| <b>Table (1)</b>  | genetic bases of several vascular malformations   | <b>14</b>   |
| <b>Table (2)</b>  | Biological Classification   | <b>20</b>   |
| <b>Table (3)</b>  | Hamburg Classification  | <b>21</b>   |
| <b>Table (4)</b>  | ISSVA Classification:   | <b>24</b>   |
|                   | a) Overview table   | <b>24</b>   |
|                   | b) ISSVA classification of benign vascular tumors   | <b>25</b>   |
|                   | c) ISSVA classification of locally aggressive vascular tumors                                     | <b>27</b>   |
|                   | d) ISSVA classification of malignant vascular tumors  | <b>28</b>   |
|                   | e) Simple vascular malformations I  | <b>29</b>   |
|                   | f) Simple vascular malformation II  | <b>30</b>   |
|                   | g) Simple vascular malformation III   | <b>32</b>   |
|                   | h) Simple vascular malformation IV  | <b>33</b>   |
|                   | i) Combined vascular malformations  | <b>34</b>   |
|                   | j) Anomalies of major named vessels   | <b>34</b>   |
|                   | k) Vascular malformations associated with other anomalies   | <b>35</b>   |
|                   | l) Provisionally unclassified vascular anomalies  | <b>36</b>   |
| <b>Table (5)</b>  | Features of vascular tumors/hemangiomas vs. vascular malformations                                | <b>39</b>   |
| <b>Table (6)</b>  | Patient's gender  | <b>143</b>  |
| <b>Table (7)</b>  | Clinical improvement (Satisfaction)   | <b>147</b>  |
| <b>Table (8)</b>  | Radiological changes in comparison between pre & post-procedure MRI diameters in three dimentions | <b>148</b>  |
| <b>Table (9)</b>  | Radiological improvements   | <b>149</b>  |
| <b>Table (10)</b> | Ethanol sclerotherapy complications   | <b>151</b>  |
| <b>Table (11)</b> | Comparison between studies  | <b>180</b>  |

### Abstract

**Background:** Congenital vascular malformations (CVMs) may contain venous, capillary, lymphatic, or arterial components in any combination and have been associated with various dysmorphic syndromes. CVMs appear at birth, persist through life and have slowly progressive course and some of them may be temporary hidden due to their deep location.

**Aim of the Work:** to evaluate the efficacy of ethanol sclerotherapy in management of low flow congenital vascular malformations and to report any possible adverse events related to this modality of treatment.

**Patients and Methods:** This case series prospective study was conducted on 40 patients having low flow CVMs at the department of Vascular Surgery at the International Medical Center (IMC), Cairo Egypt, during the period from April 2017 to April 2019.

**Results:** all patients showed good response as regard clinical improvement which was represented in patient's satisfaction, as 87.5% were satisfied and 12.5% were very satisfied. All patients showed good radiological response which was obvious in comparison of pre and post procedure MRI, as 5% were completely cured and 95% were markedly improved. All patients had no major complications, but 42.5% of patients had one or more minor complications which were subsided spontaneously or with nominal therapy without consequences or hospital admission.

**Conclusion:** Ethanol sclerotherapy is highly efficient method in treatment of low flow CVMs, but accompanied with many local complications which could be minimized when management was done by multidisciplinary team.

**Key words:** Ethanol Sclerotherapy, Low flow congenital vascular malformations

## Introduction

The blood vascular system develops in two distinct, consecutive stages vasculogenesis & angiogenesis both of them are regulated by biomechanical factors. When any defect is happened to them, it will lead to vascular malformations. When defective development occurs in the early stage of embryonic development, it will produce an extra truncular malformation, but if it happens in later stage it will produce a truncular malformation (**Lee, 2008**).

Congenital vascular malformations (CVMs) may contain venous, capillary, lymphatic, or arterial components in any combination and have been associated with various dysmorphic syndromes. CVMs appear at birth, persist through life and have slowly progressive course and some of them may be temporary hidden due to their deep location (**North PE, 2010**).

The incidence and prevalence of the CVMs were confused through the previous decades due to so much confusing definitions and classifications, the extra truncular venous malformation (VM) is the most frequent type of CVMs (**Mattassi R, et al., 2015**).

Difference between hemangioma and CVM according to previous several classifications was not clear until Judah Volkman in 1982 demonstrated that hemangioma is a lesion that has endothelial hyperplasia while CVMs have normal endothelial. 'Biological' classification divided CVMs into high-flow and low-flow lesions according to hemodynamics adding syndromes of complex cases in a group of combined complex defects. Stevan Belov in 1988 proposed 'Hamburg' classification influenced by 'Biological' classification based on morphology as well but adding more criteria. He divided CVMs into 'truncular' group which are defects related to main vessels and 'extratruncular' group which are peripheral defects that could be present into diffuse and infiltrating forms of the single type (**Mattassi R, et al., 2015**).

The International Society for the Study of Vascular Anomalies (ISSVA) published 'ISSVA' classification in 1996. Several updates were published in the last years and the most recent one -Updated ISSVA- was published in 2018 adding several subgroups to include all new discoveries (**Adams and Ricci, 2019**).

Low flow CVMs are extremely variable in type, site, extension and secondary effects so, their diagnosis should be done by multi-disciplinary team, taking detailed history, making good clinical examinations and doing necessary images under standard protocols via radiologists who have good experience about CVMs **(Lee BB, et al., 2014)**.

Unfortunately there are no widely used standard methods or protocols in treatment of CVMs. There are so many different methods in treatment of CVMs; either surgical, endo-venous laser ablation, sclerotherapy using different substances or conservative treatment according to personal experience and facilities **(Lee BB, et al., 2014)**.


Occlusion of vessels could be achieved by injecting different substances in the vessels like ethanol, bleomycin, particles, coils, glue and others. Ethanol is an excellent sclerotherapy agent for all varieties of the extratruncular CVMs. In experienced hands ethanol sclerotherapy is associated with minimum morbidity. Patients injected with ethanol require close perioperative monitoring to manage its adverse events. The most of ethanol sclerotherapy complications could be managed by conservative measures **(Lee et al., 2003, Mendonca et al., 2010)**

## **Aim of the work**

The aim of this study is to evaluate the efficacy of ethanol sclerotherapy in management of low flow congenital vascular malformations and to report any possible adverse events related to this modality of treatment.

## CVMs embryology & genetic aspect

The blood vascular system develops in two, consecutive stages (Fig. 1): firstly (vasculogenesis) differentiation of blood vessels from mesoderm-derived precursor cells, and secondary (angiogenesis) the remodeling of vessels to form arteries and veins (Flamme et al., 1997).



(Fig. 1) Vascular system development (Xu, K. & Cleaver, O. 2011)

Vasculogenesis first occurs in the yolk sac. Structures called blood islands form as hemangioblasts differentiate into endothelial and red blood cells. The endothelial cells

migrate from the blood islands and form a random vascular network called the capillary plexus. Meanwhile, the dorsal aorta forms inside the embryo; eventually, it connects the heart to the capillary plexus of the yolk sac thus completing the circulation loop (**Suami and Lee, 2017**).

Angiogenesis begins after three gestational weeks, when the heart begins to beat and blood starts circulating in the capillary plexus. Biomechanical and hemodynamic input induces active vascular remodeling. The capillary plexus is remodeled into a functional structure that includes large-caliber vessels for low-resistance rapid flow and small-caliber capillaries for diffusional flow. This remodeling occurs by the regression, sprouting, splitting, or fusion of preexisting vessels. Endothelial cells in the capillary plexus differentiate into cells with arterial and venous natures (**Suami and Lee, 2017**). Specification is believed to be related to expression of Efrin B2 in arterial and Ephrin type b receptor 2 (EphB2) in venous endothelium. Lymphatic channels are formed from veins at the six or the seventh gestational week (**Maclellan et al., 2014**).

Biomechanics and fluid dynamics regulate angiogenesis. Through embryogenesis, high local blood flow produces enlargement of vessel diameters, whereas low blood flow